Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | KGN is a tumor cell line resembling human ovarian granulosa cells that retains the capacity for steroid hormone synthesis; it was established in 1995 (and published in 2001) by Yoshihiro Nishi, Hajime Nawata, and their colleagues at Kyushu University in Japan. The cell line was derived from primary ovarian tissue and peritoneal metastatic lesions of a 63-year-old woman diagnosed with invasive adult-type ovarian granulosa cell carcinoma. KGN cells grow as an adherent monolayer and exhibit a spindle-shaped or fibroblast-like morphology. In the fields of reproductive biology, gynecology, and endocrinology, KGN is a globally recognized and indispensable *in vitro* model for studying human granulosa cell function. It is one of the few cell lines that naturally retain physiological follicle-stimulating hormone (FSH) receptor signaling pathways, intact aromatase (CYP19A1) activity, and the capacity for progesterone synthesis. Consequently, it has become the preferred human cell model for investigating follicular development, steroidogenesis, polycystic ovary syndrome (PCOS), and the biological characteristics of granulosa cell tumors (GCT). |
| Tissue | Ovary; derived from metastatic site (Peritoneum) |
| Cell Type | Granulosa-like tumor cell |
| Disease | Ovarian Granulosa Cell Tumor (GCT) |
| Morphology | Fibroblast-like / Spindle-shaped |
| Gender | Female |
| Age | 63 years |
| Product Format | Frozen |
| Growth Mode | Adherent |
| Biosafety Level | 1 (Biosafety classification aligns with global standard laboratory parameters for non-infectious human tumor cell lines) |
| Applications | 1. Establishing a "gold standard" human model for studying follicular steroidogenesis (specifically the biosynthetic pathways of progesterone and estrogen); 2. Elucidating the signal transduction mechanisms of the FSH receptor (FSHR), receptor-ligand interactions, and the downstream cyclic AMP (cAMP) signaling cascade; 3. Developing in vitro disease models for disorders of the female reproductive system (including polycystic ovary syndrome [PCOS], primary ovarian insufficiency [POI], and ovarian aging); 4. Investigating the pathogenesis and therapeutic targets of adult-type granulosa cell tumors (GCTs); 5. Evaluating Fas receptor-mediated apoptotic pathways and cell survival signaling cascades in ovarian cells. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Tumorigenic | Yes; forms progressively growing, invasive ovarian tumors when engrafted into immunocompromised host models. |
| Transformant | None; immortalized spontaneously from advanced, invasive clinical tumor tissue. |
| Karyotype | Abnormal human diploid karyotype. Typical modal chromosome number is 45. Specifically displays a recurrent deletion on the long arm of chromosome 7 and loss of chromosome 22 (45,XX,7q-,-22). |
| Apoptosis Regulation | Natively expresses the Fas receptor (CD95). Treatment with Fas-ligand or anti-Fas antibodies triggers rapid, physiological apoptosis, mirroring the cellular mechanisms of follicular atresia observed in normal human ovaries. |
| Growth Kinetics | Characterized by a relatively slow proliferation rate; typical population doubling time spans approximately 46.4 hours. |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Remove and discard all spent complete culture medium from the culture vessel. 2. Briefly rinse the cell monolayer with sterile, Ca2+/Mg2+-free PBS buffer to remove residual traces of serum containing active trypsin inhibitors. 3. Add 1.0 to 2.0 mL of pre-warmed 0.25% trypsin-0.53 mM (0.03%) EDTA solution to cover the cell layer. 4. Incubate at 37°C for 2 to 5 minutes; monitor under an inverted microscope until the cells become rounded, loosen, and completely detach. 5. Add an equal volume of complete culture medium to rapidly neutralize the enzymatic reaction. 6. Gently pipette the suspension up and down to achieve a uniform single-cell suspension. Centrifuge at approximately 125 × g for 5 minutes, carefully decant the supernatant, gently resuspend the cells in complete culture medium, and distribute into new vessels. |
| Thawing Protocol Note | KGN cells are highly sensitive to drastic pH fluctuations during the early recovery phase following thawing. Before adding the thawed cell suspension, the culture vessel containing fresh complete growth medium should be placed in a 5% CO2 incubator for at least 15 minutes to allow the medium to reach and equilibrate within the normal physiological pH range (7.0 to 7.6). |
| Medium Renewal | 2 to 3 times per week |
| Subcultivation Ratio | Split optimal, confluent cultures at a standard ratio of 1:2 to 1:4 (standard repositories) or up to 1:8 (for highly proliferative, low-passage cultures). |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | 90% Complete culture growth medium + 10% DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RO01193 | Cas9 Stable Cell Line - KGN | Inquiry |
| CSC-RR00645 | GFP Reporter Cell Line - KGN | Inquiry |
| CSC-RR00685 | Luciferase Reporter Cell Line - KGN | Inquiry |
| CSC-RO01610 | OVAL Stable Cell Line - KGN | Inquiry |
| CSC-RO01863 | GFP/OVAL Stable Cell Line - KGN | Inquiry |
| CSC-RO02116 | Luc/OVAL Stable Cell Line - KGN | Inquiry |
| CSC-RO02369 | GFP/Luc/OVAL Stable Cell Line - KGN | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.